<SEC-DOCUMENT>0001193125-25-291700.txt : 20251124
<SEC-HEADER>0001193125-25-291700.hdr.sgml : 20251124
<ACCEPTANCE-DATETIME>20251121185603
ACCESSION NUMBER:		0001193125-25-291700
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251124
DATE AS OF CHANGE:		20251121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXACT SCIENCES CORP
		CENTRAL INDEX KEY:			0001124140
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				200478229
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35092
		FILM NUMBER:		251509300

	BUSINESS ADDRESS:	
		STREET 1:		5505 ENDEAVOR LANE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53719
		BUSINESS PHONE:		608-284-5700

	MAIL ADDRESS:	
		STREET 1:		5505 ENDEAVOR LANE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53719

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXACT CORP
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d82308ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 14A Information
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Proxy Statement Pursuant to Section&nbsp;14(a) of </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>the Securities Exchange Act of 1934 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">(Amendment No.&#8195;) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>EXACT SCIENCES CORPORATION
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name of Registrant as
Specified In Its Charter) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> <FONT STYLE="white-space:nowrap">and&nbsp;0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The following email was sent to employees of Exact Sciences Corporation on the evening of
November&nbsp;21, 2025. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kevin Conroy all team email </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date</B>: November&nbsp;21, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subject</B>: Following
up on yesterday </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BCC</B>: DL Employees Exact Sciences; DL Remote Employees Exact Sciences </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Team, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yesterday was a meaningful and inspiring day for Exact
Sciences. We announced our agreement to be acquired by Abbott, a milestone that celebrates the extraordinary work of this team and opens a new chapter filled with opportunity. I feel deep pride in what we&#8217;ve built together and excitement for
what lies ahead. We will move forward with care for our people, transparency in our process, and focus on our mission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joining Abbott allows us to reach
more patients, faster. Their scale and global resources will help us prevent cancer, detect it earlier, and guide treatment for many more people. I also want to thank Robert Ford for visiting Madison yesterday. Hearing directly from him showed how
closely our values and purpose connect, as well as the strength of what we can achieve together. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we take this next step, it&#8217;s important to
remember that we will operate as an independent company until the transaction closes, which is expected sometime in Q2. During this time, please do not reach out directly to people at Abbott unless a member of the integration team, which we&#8217;ll
be forming shortly, has asked you to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is critical that we stay focused on our mission and our goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Here&#8217;s my ask for you now: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Visit our <U>Nucleus page</U> for the latest updates and materials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Read the FAQs so you have the facts and know where to go with questions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you cannot find something, notify your manager or HR. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Join any upcoming employee town halls and team sessions. Leaders will walk through details and take questions.
I will also join several of these. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I promise to keep sharing timely, honest updates as we confirm them. You&#8217;ll hear more about
what&#8217;s next after the Thanksgiving holiday. For now, I hope you take time to rest, recharge, and enjoy moments with your loved ones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On a personal
note, I&#8217;ve dedicated many years to working at this incredible company with you. We should feel proud and excited for what we&#8217;ll continue to build together through this new opportunity. Our shared purpose and the strength of this team
make all the difference. You make Exact Sciences what it is, and we&#8217;ll carry that same spirit into this next chapter. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With gratitude,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kevin Conroy </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman&nbsp;&amp; CEO</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g82308g1122022210479.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are Exact Sciences, maker of the Cologuard<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Oncotype DX<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and other life-changing<U>&nbsp;tests.</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our purpose</B>&nbsp;is to help eradicate cancer by
preventing it, detecting it earlier, and guiding personalized treatment. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Learn more at<U>&nbsp;ExactSciences.com</U> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Important Information and Where to Find It </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">In connection with the
proposed transaction, Exact Sciences Corporation (&#8220;Exact Sciences&#8221;) will file with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) a proxy statement, the definitive version of which will be sent or provided to Exact
Sciences&#8217; stockholders. Exact Sciences may also file other documents with the SEC regarding the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Exact Sciences with
the SEC. INVESTORS AND SECURITY HOLDERS OF EXACT SCIENCES ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.
Investors and security holders will be able to obtain the proxy statement (when it is available) and other documents that are filed with the SEC by Exact Sciences free of charge from the SEC&#8217;s website at https://www.sec.gov or through the
investor relations section of Exact Sciences&#8217; website at https://www.exactsciences.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Participants in the Solicitation </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Exact Sciences and its directors and certain of its executive officers and other employees may be deemed to be participants in the solicitation of proxies from
Exact Sciences&#8217; stockholders in connection with the proposed transaction. Information about the directors and executive officers of Exact Sciences and their ownership of Exact Sciences common shares is contained in the definitive proxy
statement for Exact Sciences&#8217; 2025 annual meeting of shareholders, which was filed with the SEC on April&nbsp;29, 2025, including under the headings &#8220;Information Concerning Directors and Nominees for Director,&#8221; &#8220;Information
Concerning Executive Officers,&#8221; &#8220;Corporate Governance Principles, Board Matters, and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation,&#8221; &#8220;Compensation and Other Information Concerning Named Executive
Officers&#8221; and &#8220;Securities Ownership of Certain Beneficial Owners and Management.&#8221; Additional information regarding ownership of Exact Sciences&#8217; securities by its directors and executive officers is included in such
persons&#8217; SEC filings on Forms 3 and 4. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the stockholders of Exact Sciences in connection with the proposed
transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be included in the proxy statement relating to the proposed transaction when it is filed with the SEC. Free copies of the proxy
statement relating to the proposed transaction and free copies of the other SEC filings to which reference is made in this paragraph may be obtained from the SEC&#8217;s website at https://www.sec.gov or through the investor relations section of
Exact Sciences&#8217; website at https://www.exactsciences.com. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Forward-Looking Statements </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">This communication contains forward-looking statements about, among other things, the proposed acquisition of Exact Sciences by Abbott Laboratories.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, the following: the
possible inability of the parties to consummate the proposed transaction on a timely basis or at all; the possible inability of the parties to satisfy the conditions precedent to consummation of the proposed transaction, including necessary
regulatory approvals and the requisite vote by Exact Sciences&#8217; stockholders, on a timely basis or at all; the possible occurrence of any event, change or other circumstance that could give rise to the termination of the parties&#8217;
definitive agreement for the proposed transaction (the &#8220;Merger Agreement&#8221;); the risk that the Merger Agreement may be terminated in circumstances that require Exact Sciences to pay a termination fee; the possibility that competing offers
may be made; the potential adverse impact on Exact Sciences of contractual restrictions under the Merger Agreement that limit Exact Sciences&#8217; ability to pursue business opportunities or strategic transactions; risks relating to significant
transaction costs associated with the proposed transaction and the possibility that the proposed transaction may be more expensive to complete than anticipated; potential adverse effects of the announcement or pendency of the proposed transaction,
or any failure to complete the proposed transaction, on the market price of Exact Sciences&#8217; common stock or on the ability of Exact Sciences to develop and maintain relationships with its personnel (including Exact Sciences&#8217; ability to
attract and retain highly qualified management and other scientific personnel) and customers, suppliers and others with whom it does business or otherwise on Exact Sciences&#8217; business, financial condition, results of operations and financial
performance; risks related to diversion of management&#8217;s attention from Exact Sciences&#8217; ongoing business operations due to the proposed transaction; and the risk of litigation and/or regulatory actions related to the proposed transaction
or Exact Sciences&#8217; business and the outcome of any such litigation or regulatory action. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The risks described above are not exhaustive. Other
important risks and uncertainties affecting Exact Sciences and its business are described in the Risk Factors sections of Exact Sciences&#8217; most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent
Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and in its other reports filed with the SEC. Exact Sciences undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made
from time to time, whether as a result of new information, future developments or otherwise. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g82308g1122022210479.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g82308g1122022210479.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W (T# 2(  A$! Q$!_\0
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?!<\+_#_PUX0=I=(T]4G88,\AWOCTR>GX5TU%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
